Select Page

20+ years of experience.

PsychoGenics has built a vibrant contract research business based on high-capacity and high-quality testing with fast turnaround and delivery of results. Since our founding in 1999 we have performed tens of thousands of studies for hundreds of clients averaging 350 studies per year. Over 90 percent of our clients return for repeat business, attesting to the quality of service provided.

Through our journey, our team of talented scientists have developed innovative AI-driven drug discovery platforms and analytical tools leading to shared-risk partnerships and numerous drug candidates in clinical trials.

Our fee-for-service and partnered research have contributed to improved and needed treatments for patients suffering from severely disabling neuropsychiatric disorders.

Management Team

Mark Varney, Ph.D.

Chief Scientific Officer

Read bio

Dani Brunner, Ph.D.

Chief Innovations Officer

Read bio

Taleen Hanania, Ph.D.

EVP, External Client Affairs

Read bio

Geoff Varty, Ph.D.

EVP, Research Operations

Read bio

Sylvie Ramboz, Ph.D.

VP, Neurodegenerative Disorders

Read bio

Afshin Ghavami, Ph.D.

VP, Research Operations

Read bio

Steven C. Leiser, Ph.D.

Sr. Director, Translational EEG

Read bio

Leslie Street, Ph.D.

VP, Medicinal Chemistry

Read bio

Christina Leahy

VP, QA and Regulatory Affairs

Read bio

Mitchell Silverstein

VP, Facilities and Operations

Read bio

Cindy Hsu, J.D.

General Counsel

Read bio

Board Of Directors

Scientific Advisory Board

Corporate Social Responsibility

At PsychoGenics, we are pioneering new approaches to CNS drug discovery. Together with our partners and clients, we are committed to making a difference for patients, our employees, the environment and the communities where we live and work. The foundation for these commitments is reflected in our approach to corporate social responsibility (CSR).

PsychoGenics is committed to collaborating with academia, government institutions, companies, and foundations, big and small, to help discover new treatments. Our focus on neuroscience, our deep scientific expertise, and our innovative approach to drug discovery has resulted in several novel treatments in clinical trials with potential to transform the lives of patients suffering from disabling neuropsychiatric disorders.

Our employees care deeply and believe in the work we do, knowing that we can make a meaningful difference in patients’ lives. We have built a diverse and inclusive culture where individuals bring a broad range of capabilities, experiences, and perspectives and are encouraged to collaborate, lead, and grow. We reward hard work and creativity and we encourage our employees to take the initiative and seek out growth opportunities.

PsychoGenics is committed to minimizing the environmental effect of its operations through the promotion of environmental awareness and use of online communications and teleconferencing tools, as well as running an energy-efficient LEED-certified building and practicing sustainable waste management. We also identify and assess our environmental impacts on an ongoing basis.

CONTACT

PsychoGenics Inc.
215 College Road, Paramus, NJ 07652

Email: info@psychogenics.com
Phone: (914) 406-8019

Fax: (914) 406-8090

 

Copyright © 2020 PsychoGenics Inc.

All rights reserved.

CONTACT

PsychoGenics Inc.
215 College Road, Paramus, NJ 07652

Email: info@psychogenics.com
Phone: (914) 406-8019

Fax: (914) 406-8090

Copyright © 2020 PsychoGenics Inc.

All rights reserved.